[{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ElevateBio \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LETI-101","moa":"Mutant huntingtin protein level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ElevateBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Urology","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ J.P. Morgan"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Kite Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Kite Pharma"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Morgan Stanley"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALVR106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"AlloVir \/ AlloVir"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALVR109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Blackrock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ Blackrock"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio \/ ElevateBio"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio \/ Undisclosed"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"5","companyTruncated":"ElevateBio \/ ElevateBio"},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ AyurMaya Capital Management Fund"},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio \/ The Invus Group"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Kelonia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ ElevateBio"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Amazon Web Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ Amazon Web Services","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ Amazon Web Services"}]

Find Clinical Drug Pipeline Developments & Deals by ElevateBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The combined company will focus on the development of TH103, a fully humanized, recombinant fusion protein, for patients with neovascular age-related macular degeneration.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          March 18, 2025

                          Lead Product(s) : TH103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Kalaris Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The collaboration aims to accelerate the discovery and development of CRISPR gene editing therapeutics through AI for treating cancer and genetic diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Amazon Web Services

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : LETI-101 is a selective reducer of disease-causing mutant huntingtin (mHTT) protein, It is being evaluated in patients with huntington's disease.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 24, 2025

                          Lead Product(s) : LETI-101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The combined company will focus on the development of TH103, a fully humanized, recombinant fusion protein, for patients with neovascular age-related macular degeneration.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          November 08, 2024

                          Lead Product(s) : TH103

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Kalaris Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The collaboration aims to explore novel approaches to improve therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR incubator system for cell therapy research and development.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Xcell Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ALVR105 (posoleucel) is a T-lymphocyte cell therapy which is under phase 3 clinical development for the treatment of adenovirus infections, BK virus infections & Epstein-Barr virus infection.

                          Product Name : Viralym-M

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 22, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The company intends to use the net proceeds to complete enrollment and achieve data readouts in all three of its ongoing Phase 3 trials of its lead multi-virus specific candidate, Viralym-M (posoleucel), an allogeneic, off-the-shelf multi-virus specific ...

                          Product Name : Viralym-M

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $7.5 million

                          Deal Type : Public Offering

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The proceeds will advance the company’s technology platforms, Life Edit gene editing, iPSCs, and RNA, cell, protein, vector engineering and BaseCamp®, to accelerate the design, manufacturing, and development of cell and gene therapies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 24, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : AyurMaya Capital Management Fund

                          Deal Size : $401.0 million

                          Deal Type : Series D Financing

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging immunity between conditioning and reconstitution of t...

                          Product Name : Viralym-M

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 15, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging immunity between conditioning and reconstitution of t...

                          Product Name : Viralym-M

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          January 09, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank